PHILLIP BRANCH CHAPPELL, MD
Psychiatric in New Haven, CT

License number

Connecticut CT028100

Personal information

See more information about PHILLIP BRANCH CHAPPELL at radaris.com

Name

Address

Phone

Phillip Chappell

153 Elm St, Guilford, CT 06437

(203) 457-9049

Phillip B Chappell, age 76

153 Elm St, Guilford, CT 06437

(203) 457-9049

Professional information

See more information about PHILLIP BRANCH CHAPPELL at trustoria.com

Phillip Branch Chappell, New Haven CT

Specialties:

Psychiatrist

Address:

230 S Frontage Rd, New Haven, CT 06519

Education:

University of North Carolina, School of Medicine - Doctor of Medicine
Yale-New Haven Children's Hospital - Fellowship - Child Psychiatry
Duke University Hospital - Residency - Psychiatry

Board certifications:

American Board of PsychiatryÂ andÂ Neurology Certification in Psychiatry (Psychiatry and Neurology), American Board of PsychiatryÂ andÂ Neurology Sub-certificate in Child and Adolescent Psychiatry (Psychiatry and Neurology)

Dr. Phillip B Chappell, New Haven CT - MD (Doctor of Medicine)

Specialties:

Child & Adolescent Psychiatry

Address:

230 S Frontage Rd, New Haven 06519
(203) 785-5880 (Phone)

Certifications:

Child & Adolescent Psychiatry, 1992, Psychiatry, 1989

Awards:

Healthgrades Honor Roll

Languages:

English

Education:

Medical School
University of North Carolina At Chapel Hill
Graduated: 1984
Duke University Hospital
Yale Child Study Ctr

Aralkyl And Aralkylidene Heterocyclic Lactams And Imides

US Patent:

6423708, Jul 23, 2002

Filed:

Dec 8, 2000

Appl. No.:

09/733346

Inventors:

Megan Ann Gibbs - Noank CT
Harry Ralph Howard - Bristol CT
Jeffrey Scott Sprouse - Stonington CT
Joel Barry Schachter - East Lyme CT
Phillip Branch Chappell - Guilford CT

Assignee:

Pfizer INC - New York NY

International Classification:

A61K 31538

US Classification:

5142278, 5142358, 544 59, 544 60, 544121, 558426

Abstract:

The present invention relates to compounds of the formula I wherein R , R , R , X, Y and the dashed line are as defined in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use as psychotherapeutic agents.

Combination Treatment For Depression, Anxiety And Psychosis

US Patent:

2002009, Jul 18, 2002

Filed:

Dec 5, 2001

Appl. No.:

10/001827

Inventors:

Phillip Chappell - Guilford CT, US
Stevin Zorn - North Stonington CT, US

Assignee:

Pfizer Inc

International Classification:

A61K031/4985, A61K031/506, C07D489/04

US Classification:

514/249000, 544/238000, 544/295000, 544/349000

Abstract:

The present invention relates to a method of treating depression, anxiety or psychosis in a mammal, including a human, by administering to the mammal a D4 receptor antagonist in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a D4 receptor antagonist and an antidepressant or an anxiolytic agent.

Pharmaceutical Uses For Fluoroalkoxybenzylamino Derivatives Of Nitrogen Containing Heterocycles

US Patent:

2003011, Jun 19, 2003

Filed:

Jul 29, 2002

Appl. No.:

10/208274

Inventors:

Phillip Chappell - Guilford CT, US
Brian O'Neill - Old Saybrook CT, US
Mario Saltarelli - Mystic CT, US

Assignee:

Pfizer Inc.

International Classification:

A61K031/55, A61K031/46, A61K031/47, A61K031/4745

US Classification:

514/217010, 514/304000, 514/305000, 514/286000, 514/307000

Abstract:

The present invention relates to methods of treating various CNS and other disorders by adminstering fluoroalkoxybenzylamino derivatives of nitrogen containing heterocyclic compounds, and specifically, by administering compounds of the formula wherein Q, X, Xand Xare as defined below, and their pharmaceutically acceptable salts.

Combination Treatment For Depression, Anxiety And Psychosis

US Patent:

2004004, Mar 11, 2004

Filed:

Sep 3, 2003

Appl. No.:

10/654151

Inventors:

Phillip Chappell - Guilford CT, US
Stevin Zorn - Ann Arbor MI, US

Assignee:

Pfizer Inc

International Classification:

A61K031/506, A61K031/501, A61K031/498, C07D487/04

US Classification:

514/249000, 544/238000, 544/295000, 544/350000

Abstract:

Pharmaceutical Uses For Fluoroalkoxybenzylamino Derivatives Of Nitrogen Containing Heterocycles

US Patent:

2008013, Jun 5, 2008

Filed:

Aug 5, 2004

Appl. No.:

10/911872

Inventors:

Phillip Branch Chappell - Guilford CT, US
Brian Thomas O'Neill - Haddam CT, US
Mario David Saltarelli - Lake Bluff IL, US

International Classification:

A61K 31/439, A61K 31/445, A61K 31/4525, A61P 13/10

US Classification:

514305, 514329, 514326

Abstract:

A method of treating overactive bladder disorders characterized by involuntary neurogenic detrusor contractions associated with the pathology of multiple sclerosis by administering fluoroalkoxybenzylamino derivatives of nitrogen containing heterocyclic compounds, and specifically, by administering compounds of the formulawherein Q, X, Xand Xare as defined below, and their pharmaceutically acceptable salts.

Method Of Treating Tourette's Syndrome And Obsessive Compulsive Disorder

US Patent:

6127373, Oct 3, 2000

Filed:

Sep 3, 1998

Appl. No.:

9/146289

Inventors:

Phillip B. Chappell - Guilford CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 31495, A61K 3150

US Classification:

514254

Abstract:

A method for treating Tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.